Takeda downsizes after cell therapy exit Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 2 October, 2025

Healthcare's #1 must-attend innovation event. Join industry leaders and stakeholders converge to ignite change, form strategic partnerships, and explore transformative solutions for a healthier tomorrow. sponsored by HLTH, Inc.

presented by De­sign It Right: Eval­u­at­ing AAV Man­u­fac­tura­bil­i­ty Through Mol­e­c­u­lar and Up­stream Op­ti­miza­tion

spotlight Watch Post-Hoc Live: Unpacking Trump and Pfizer’s 'most favored nation' drug price deal

news A year after collaborating with Gilead, Cartography maps out its own Phase 1 with $67M Series B Galapagos says it’s weeks away from decision on cell therapy business review Takeda lays off 137 workers following cell therapy stoppage Exclusive: Gene therapy startup launches with $11M to tackle aging disease of the eye Exclusive: Upcoming ACIP meeting may move to December, administration official says

Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Big Pharma is doubling down. Startups are going all in. Who’s actually making AI work in drug R&D? Join the debate with expert discussions and insights you won’t want to miss. Register today.

endpoints pharma Trump’s threatened pharma tariffs won’t start Wednesday despite prior warning, White House says Did Pfizer get a good deal with Trump? Wall Street thinks so CMS spells out new orphan drug protections in IRA negotiation guidance Biogen owes Genentech $88M in 'tail' royalties from Tysabri, court rules

in case you missed it 1. Takeda stops all work in cell therapy  2. Exclusive: French startup's gene therapy dramatically reduces urinary incontinence in spinal cord injury patients 3. FDA rejects treatment for rare copper deficiency over manufacturing 4. Ansa Biotechnologies closes $54.4M Series B to boost US DNA manufacturing  5. After building Ochre Bio, Jack O'Meara's newest biotech raises $21M for neuro siRNAs 6. Vertanical unpacks Phase 3 success for cannabis-based painkiller 7.